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Introduction
Centella asiatica (L.) Urb. (Asiatic pennywort, Gotu kola, or Bua-bok) belongs to the Apiaceae family and is commonly found in tropical areas of Southeast Asia, India, South Africa, South America, and Eastern Europe [1] [2] [3] . The plant has been used as traditional medicine for a long time and, in line with this, supporting pharmacological effects have been well documented in a number of preclinical studies, suggesting the potential for further development of C. asiatica into a phytopharmaceutical product [4] [5] [6] [7] [8] [9] [10] [11] . Considerable fluctuations in the chemical composition of the plant from different origins have resulted in inconsistencies of bioactive constituents of the plant extract, which poses a major problem for its application as a natural medicine. To overcome such a problem, we prepared ECa 233 which is a standardized extract of C. asiatica [12] defined as a white to off-white powder containing triterpenoid glycosides not less than 80 % with a ratio of madecassoside to asiaticoside of 1.5 ± 0.5:1 (▶Fig. 1) [13, 14] . ECa 233 has demonstrated various pharmacological effects such as the acceleration of second degree burn wound healing in Wistar rats [15] , as well as a reduction in pain, ulcer size, and erythema score of minor recurrent aphthous ulcerations in human subjects [16] . In the central nervous system, the anxiolytic effects of 100 mg/kg ECa 233, given orally, have been shown in mouse models of acute and chronic stress [14] . ECa 233 was also found to ameliorate learning and memory deficits induced by intracerebroventricular injection of amyloid peptide in a mouse model [17] . The extract also has a neuritogenic effect on human neuroblastoma cells via the upregulation of activated ERK1/2 and Akt [18] . An oral dose up to 10 g/kg has modest toxicity in both acute and subchronic tests in rodents [19] . Taken together, ECa 233 may be a good phytomedicine candidate for the treatment of some neurological disorders. However, the pharmacokinetic data needed for appropriate dosing are rather scant.
Recently, a single-dose pharmacokinetic study of orally given ECa 233 was conducted in rats [20] . It was found that, after a single oral doses of ECa 233 at 50, 100, and 200 mg/kg, madecassoside and asiaticoside were rapidly absorbed, reaching their respective C max (madecassoside 1 654 ± 884, 5 664 ± 3 947, and 9 020 ± 5 744 µg/L; asiaticoside 318 ± 192, 1 283 ± 1 089, and 4 028 ± 3 157 µg/L) within 5-15 min. Both compounds were distributed into the brain and other tissues and were eliminated mainly as madecassic acid and asiatic acid via feces [21] . The present study further examines the single and multiple dosing pharmacokinetic behavior of ECa 233 at its effective dose for the treatment of chronic neurological conditions (100 mg/kg daily) in Wistar rats. The tissue distribution of the major components of ECa 233, namely madecassoside and asiaticoside, into pharmacologically related organs was also conducted to determine their steady state levels after multiple oral dosing for 7 days. Determination of triterpenoid glycosides and triterpenic acid metabolites was performed by LC-MS/ MS. In addition, the mRNA expression of efflux transporters in the liver and small intestine was determined by qPCR in order to access their effects on the pharmacokinetic behaviors of madecassoside and asiaticoside after multiple oral dosing of ECa 233. The data obtained from this study will help with determining the appropriate dose of ECa 233 for long-term use and highlights possible drugherb interactions of ECa 233.
Results
Rats receiving 100 mg/kg/day of oral ECa 233 for 7 days showed no significant physical changes or abnormalities. AST and ALT levels at post-treatment (24 h on day 7) did not change significantly from those of pretreatment (0 h on day 1), indicating marginal effects of ECa 233 on liver functions. Creatinine levels, reflecting kidney status, showed no significant changes after multiple oral dosing for 7 days. All biochemical parameters were within the normal ranges of healthy Wistar rats (▶ Table 1 ).
Plasma concentration-time profiles of madecassoside and asiaticoside, the major components of ECa 233, were constructed on Table 2 ). Multiple oral doses of ECa 233 (100 mg/ kg) for one week resulted in a significant decrease in the C max and AUC (0-24) of madecassoside and asiaticoside compared with the single oral dose on day 1 (p < 0.05). C max decreased by 83.4 and 83.6 % and AUC (0-24) decreased by 78.2 and 72.2 % for madecassoside and asiaticoside, respectively. T max at day 7 was slightly delayed, but did not differ significantly from that observed on day 1. Madecassoside and asiaticoside showed good tissue distribution after oral administration of 100 mg/kg ECa 233 for 7 consecutive days (▶Table 3). Both compounds reached the brain, skin, spleen, liver, kidney, and stomach in similar distribution patterns with the AUC (0-4) up to 44.5 µg · h/g of tissue. Interestingly, the AUC (0-4) of all tissues, except the stomach, after ECa 233 dosing on day 7 was sig-nificantly higher than that after single oral dosing (day 1) in which madecassoside and asiaticoside in the brain were increased by approximately 4-and 6-fold, respectively. Excretion of triterpenoid glycosides was observed within 24 h after dosing on days 1 and 7 (▶Table 4). Madecassoside and asiaticoside were detected in negligible amounts in the urine. Madecassic acid and asiatic acid, the expected triterpenic acid metabolites of madecassoside and asiaticoside, which were found at negligible levels in plasma, were detected mainly in the feces and had higher percent recoveries than the parent compounds on days 1 and 7.
The mRNA expression levels of Abcb1a, Abcb1b, Abcc2, and Abcg2 in the liver and small intestine were quantified (▶ Fig. 3 ). There were no notable changes in any of the observed efflux transporter mRNAs in the liver of most tested groups. The mRNA expression of Abcb1a and Abcc2 was significantly upregulated in the small intestine. There was about a 2-fold increase in Abcb1a expression in the duodenum and jejunum, and a 2-to 4-fold increase of Abcc2 mRNA expression was clearly observed throughout the small intestine of the animals receiving multiple doses of ECa 233 for 7 days.
Discussion
ECa 233 is a standardized extract of C. asiatica that consistently contains designated levels of madecassoside and asiaticoside [12] . The pharmacological effects of ECa 233 in decreasing anxiety [14] and ameliorating learning and memory deficits indicate the therapeutic potential of this extract [17, 18] . Development of ECa 233 as an alternative medicine for the treatment of some central nervous system disorders requires pharmacokinetic data following longterm administration. In this study, the multiple-dose pharmacokinetics of 100 mg/kg given orally for 7 days were examined in adult male Wistar rats. No animals showed significant changes in physical appearance or biochemical parameters, indicating normal kidney and liver function. These results are consistent with the good safety profiles of ECa 233 in previous acute and subchronic toxicity studies [19] .
The pharmacokinetic parameters of madecassoside and asiaticoside were determined from the plasma concentration-time profiles on days 1 and 7 using non-compartmental analysis. The significant 80 % decreases in C max and AUC (0-24) of madecassoside and asiaticoside after 7 consecutive days of ECa 233 treatment indicate the possibility that the extract might have an inductive effect on efflux transporters or on drug metabolizing enzymes, as previously demonstrated by other herbal products [22, 23] . Madecassoside has been found to be a substrate for efflux transporters such as PGP and MRP2 [24] . Accordingly, our qPCR results did demonstrate in- creasing mRNA levels of Abcb1a and Abcc2, which are responsible for PGP and MRP2 expression. These two transporters could be upregulated in the small intestine, especially the duodenum and jejunum where most drug absorption takes place. Together with our previous findings, ECa 233 neither altered the total CYP content nor the CYP1A1, CYP1A2, CYP2B1/2B2, CYP2E1, and CYP3A activities after 90 days of treatment [25] . It is suggestive that upregulation of the efflux transporters, PGP and MRP2, might underlie the decreases in the C max and AUC (0-24) of madecassoside and possibly asiaticoside as well. On day 1 of oral dosing with ECa 233, the T max of madecassoside and asiaticoside was found to be 0.08-0.17 h and tended to be delayed after multiple dosing of ECa 233. A small second peak 4 h after dosing could possibly be accounted for by the enterohepatic circulation as proposed for pure madecassoside in a linked-rat model [24] . The tissue distribution study showed that madecassoside and asiaticoside reached various organs such as the skin, stomach, and especially the brain in which ECa 233 apparently exerts its pharmacological effects. High amounts of both triterpenoid glycosides in brain tissue is key evidence to confirm that madecassoside and asiaticoside are the bioactive compounds responsible for the pharmacological effects of ECa 233, as previously stated in a single dosing pharmacokinetic study [20] . In the present study, both triterpenoid glycosides appeared to be rapidly absorbed from the intestine into the circulatory system and extensively distributed into the internal organs after multiple oral dosing. Accumulation of these two glycosides in the target organs was apparent and resulted in a significantly higher tissue AUC (0-4) of madecassoside and asiaticoside on day 7, while their respective plasma concentrations were decreasing. Hence, our study suggests that it is best to determine the tissue levels of the active constituents of the herbal extract in concurrent with their respective plasma concentration-time profiles in multiple dosing pharmacokinetic studies.
Madecassic acid and asiatic acid were initially suggested to be active triterpenic metabolites [26] formed in vivo by esterase hydrolytic cleavage or acid hydrolysis of the sugar moiety from the parent triterpenoid glycosides [27] in a stepwise process [24] . The levels of these metabolites were minimal in plasma and tissue samples, but they were abundantly found in feces. The calculated percent recoveries within 24 h post-treatment on days 1 and 7 were consistent with our previous studies showing that ECa 233 was primarily excreted via feces and mainly as madecassic acid and asiatic acid [20, 21] . This result could imply that the parent triterpenoid glycosides underwent a hydrolytic reaction to remove the sugar moiety and were then metabolized into the acid metabolites in the gastrointestinal tract. A relatively larger amount of triterpenic acid metabolites, in comparison with their respective parent triterpenoid glycosides, were found in the feces on days 1 and 7. A small amount of triterpenic acid metabolites was excreted via the urinary system, consistent with their lipophilic properties (madecassic acid: . Therefore, both of compounds were excreted mainly by the hepatobiliary system, rather than the urinary system.
In conclusion, a significant accumulation of madecassoside and asiaticoside in the tissue compartments was apparent despite an 80 % decrease in their respective plasma concentrations at day 7. This decrease in plasma triterpenoid glycosides could be accounted for by the inductive effect of ECa 233 on intestinal Abcb1a and Abcc2 mRNA expression. The information obtained in this study suggests that no dosage adjustment is required for long-term use of ECa 233, but calls attention to the possibility of drug-herb interactions when ECa 233 is coadministered long term with conventional PGP and MRP2 substrate drugs. 
Materials and Methods

Animals
Male Wistar rats aged 12 weeks old were obtained from the National Laboratory Animal Center, Mahidol University. They were housed with free access to food ad libitum under a controlled temperature and 12-h light-dark cycle prior to multiple dosing experiments. Rats with a weight of 400 to 600 g were placed in metabolic cages and fasted for 12 h with free access to water before a daily dosing of ECa 233, rifampicin, or vehicle (20 % DMSO/NSS). The animal experiments were conducted according to a protocol approved by the Institutional Animal Care and Use Committee of the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand (approval number 13-33-007 and approval date: March 4, 2013) .
Pharmacokinetic experiments
Rats received a daily oral administration of freshly prepared ECa 233 (50 mg/mL in 20 % DMSO/NSS) at a dose of 100 mg/kg for 7 days. Blood (400 µL) was collected via the lateral tail vein into preheparinized tubes on days 1 and 7 at 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing. Blood samples were centrifuged at 1 500 × g for 10 min to acquire approximately 200 µL of plasma. Urine and feces were collected separately from metabolic cages on days 1 and 7 for 0-24 h after dosing. Urine volume and feces weight were recorded for the calculation of percent recovery. On day 7, some rats were euthanized at 1, 2 and 4 h after oral dosing to collect the brain, liver, kidney, spleen, stomach, and skin. Tissue samples were washed in normal saline to remove blood. All rats were anesthetized with isoflurane to reduce pain and injury during drug administration and sample collection. All biological samples were kept at − 20 °C until analysis. Plasma samples at 0 h on day 1 and 24 h on day 7 were also used for evaluation of creatinine, AST, and ALT levels to examine the effects of ECa 233 on kidney and liver functions.
Sample preparation
Methanol was used as a precipitating agent to prepare all biological samples by protein precipitation. Plasma and urine samples were thawed at room temperature, and 50 µL of each sample were mixed with 200 µL of methanol containing 10 ng of glycyrrhetinic acid (IS). The mixture was centrifuged at 5 000 × g for 10 min, and 10 µL of supernatants were analyzed by LC-MS/MS using optimized conditions and parameters. Approximately 50 mg of feces or tissue were combined with 200 µL of methanol containing 10 ng of IS, homogenized in an ice bath, and then processed in the same manner as the plasma and urine samples. Blank matrices were used to dilute some samples before protein precipitation if the concentration of analytes exceeded the linearity range of detection in LC-MS/MS.
LC-MS/MS analysis
LC-MS/MS analysis was carried out using methods previously mentioned in a pharmacokinetic study of a single oral dosing of ECa 233 [20] . In brief, an LC-MS/MS system comprising of an Eksigent Ekspert UPLC 100 liquid chromatograph equipped with a QTRAP 6500 mass spectrometer controlled by Analyst software version 1.6 (AB Sciex Pte. Ltd.) was used for analytical procedures. The stationary phase was a Synergi 4 µm Fusion-RP C18 column 50 × 2 mm (Phenomenex, Inc.) with a 40 °C oven temperature. With the optimized LC-MS/MS system, the retention times of madecassoside, asiaticoside, madecassic acid, asiatic acid, and glycyrrhetinic acid were 1.79, 1.82, 1.93, 1.99 and 2.12 min, respectively. The calculated percent recoveries were 78-93 % for all analytes. Calibration curves of triterpenoid glycosides and triterpenic acids showed good linearity with R 2 > 0.99 for 0.5-300 µg/L. The lower limit of detection was 0.1-0.5 µg/L, and intraday and inter-day precision and accuracy were within ± 10 %.
Quantitative real-time PCR
Rats were divided into four groups and orally treated for 7 days as vehicle (negative control), 50 mg/kg ECa 233 (low dose), 100 mg/ kg ECa 233 (high dose), and 250 mg/kg rifampicin (positive control). Subsequently, they were euthanized to collect liver and intestinal mucosal cells from the duodenum, jejunum, and ileum parts of the small intestine. Total RNA was then isolated from tissue homogenates using a Gen Elute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich Corp.) according to the company instructions. The cDNA was consequently prepared by reverse transcription of each RNA sample with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR was performed on an Mx3000P Real-Time QPCR System (Agilent Technologies Inc.). The following primers were used for amplification of rat Gapdh: forward 5ʼ-CTG TGG TCA TGA GCC CCT CC-3ʼ and reverse 5ʼ-CGC TGG TGC TGA GTA TGT CG-3ʼ, Abcb1a: forward 5ʼ-TGA ACT GTG ACC ATG CGA GAT GTT AAA TA-3ʼ and reverse 5ʼ-GTC TCT GAA GAC TCT AAA ATG GAC TAA ATG-3ʼ, Abcb1b: forward 5ʼ-CCA GGA GAG AAG ACT TAG TTC G-3ʼ and reverse 5ʼ-GGC AAA CAC TGG TTG TAT GCA C-3ʼ, Abcc2: forward 5ʼ-TTC ACG GGC ACA TCA CCA-3ʼ and reverse 5ʼ-ATT CGG ACC CAA ACA GGA TG-3ʼ, Abcg2: forward 5ʼ-GTT TGG ACT
